683 Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

683 Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-38,058	Closed	-$222K	–	348
2022 Q4	$222K	Buy	+38,058	New	+$200K	0.02%	147

683 Capital Management's CNCE Position: Q1 2023 in Review

683 Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 38,058 shares — an estimated $222K sold.

683 Capital Management first reported a position in CNCE in Q4 2022 and held it in 1 quarter. The position peaked at $222K in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

683 Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
683 Capital Management sold 38,058 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $222K.
683 Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
683 Capital Management's Concert Pharmaceuticals, Inc. position peaked at $222K in Q4 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.